口服强力霉素联合外用人重组干扰素α栓对清除宫颈中解脲支原体34例临床观察

Clinical Observation of the Application of Oral Farmodoxi Combined with Human Recombination Interferon-α Embolus in Clearing Ureaplasma Urealyticum in 34 Female Vervix Cases

目的 :研究人重组干扰素α栓在女性宫颈解脲支原体 (Uu)清除应用中的价值。方法 :74例宫颈Uu单纯检出者 ,随机分为人重组干扰素α栓联合强力霉素组 (治疗组 )和单纯应用强力霉素组 (对照组 ) ,其中治疗组 3 4例 ,对照组 40例 ,分别观察两组疗效。结果 :治疗组和对照组之间痊愈率无显著性差异 ( χ2 =4 0 2 ,P =0 1 3 4) ,而治疗组总有效率 ( 94 1 % )高于对照组的总有效率 ( 77 5 % ) ,两者比较有显著性差异 ( χ2 =4 0 1 ,P <0 0 5 )。结论 :临床上干扰素α栓剂与抗菌素的联合应用 ,对于女性子宫颈中Uu清除有一定的疗效。

Objective:To study the clinical value of human recombination Interferon-α embolus combined with oral Farmodoxi in clearing Uu in female vervix. Methods:74 cases with Uu were divided into the study group (34 cases) treated by human recombination Interferon-α embolus combined with farmodoxi and the control group (40 cases) treated by farmodoxi only. Results:The result showed that the total effective rate in the study group(94.1%) was higher than that in control (77.5%), and the difference between two groups was significantly(χ 2=4.01,P=0.045), and the ratios of recovering in two groups were no statistical significance(χ 2=4.02,P=0.134). Conclusion:We find that combination therapy have certain effect for the clearance of Uu in female cervixs.